Results 171 to 180 of about 55,752 (265)

Clinical manifestations, prognostic impact, and relapse in polyarteritis nodosa: a systematic review and meta-analysis. [PDF]

Rheumatol Int
Taprantzis N, Kasimeri ME, Chrysikos D, Shihada A, Samolis A, Tsakotos G, Liga M, Troupis T.   +7 more
europepmc   +1 more source

LED Photobiomodulation for Pain Reduction in Temporomandibular Disorder: A Randomized, Controlled, and Blinded Clinical Trial

Journal of Biophotonics, Volume 19, Issue 3, March 2026.
This randomized, controlled, and blinded trial demonstrated that photobiomodulation (PBM) with 850 nm (infrared) and 660 nm (red) LED clusters effectively reduced pain in patients with temporomandibular dysfunction (TMD). ABSTRACT This clinical, randomized, controlled, and blinded trial evaluated photobiomodulation (PBM) using 850 nm (infrared) and 660 
Lucía Píriz Trindade, Maria Jose Urruty, Laura Hermida Bruno, Federico Todeschini, Luis Eduardo Pascuali Moya, Valentina Lestido, Tainá Caroline dos Santos Malavazzi, Lara Jansiski Motta, Sandra Kalil Bussadori, Kristianne Porta Santos Fernandes, Anna Carolina Ratto Tempestini Horliana, Raquel Agnelli Mesquita‐Ferrari   +11 more
wiley   +1 more source

TNF-alpha inhibitors reduce the incidence of PsA in patients with psoriasis: a propensity score-matched cohort study. [PDF]

Rheumatology (Oxford)
Piaserico S, Megna M, Bardazzi F, Magnano M, Giovanardi G, Odorici G, De Simone C, Ramonda R, Conti A, McGonagle D.   +9 more
europepmc   +1 more source

Safety and Effectiveness of Pharmacy Compounded Chenodeoxycholic Acid Capsules for Patients With Cerebrotendinous Xanthomatosis

Journal of Inherited Metabolic Disease, Volume 49, Issue 2, March 2026.
ABSTRACT Chenodeoxycholic acid (CDCA) is an essential drug for patients with rare metabolic disease cerebrotendinous xanthomatosis (CTX). To ensure continuation of treatment, the Amsterdam UMC hospital pharmacy developed pharmacy compounded CDCA capsules when the authorized CDCA capsules were no longer available for Dutch patients.
Natalja Bouwhuis, Soumia Majait, Yasmin Polak, Aylene de Jong, Bart A. W. Jacobs, Frédéric M. Vaz, Willemijn G. Leen, E. Marleen Kemper, Eleonora L. Swart, Carla E. M. Hollak   +9 more
wiley   +1 more source

Temporomandibular disorder in children with juvenile idiopathic arthritis with and without temporomandibular joint involvement compared to controls - a two-year prospective multicenter cohort study. [PDF]

BMC Oral Health
Halbig JM, Stoustrup P, Kristensen KD, Frid P, Rypdal V, Songstad NT, Augdal TA, Fischer J, Gil EG, Cetrelli L, Lundestad A, Angenete O, Aukland SM, Tylleskär K, Rosen A, Skeie MS, Rygg M, Rosendahl K, Jönsson B, Nordal E.   +19 more
europepmc   +1 more source

Pegvaliase Treatment for Adolescents With Phenylketonuria: A Multi‐Site Study

JIMD Reports, Volume 67, Issue 2, March 2026.
ABSTRACT Phenylketonuria (PKU) is an inherited metabolic disorder causing elevated phenylalanine (Phe) levels and neurocognitive impairment if left untreated. While dietary therapy remains the treatment standard, adherence declines during adolescence. Pegvaliase, an injectable enzyme therapy approved for adults > 18 years in the United States, lowers ...
Suzanne Hollander, Briana Valli, Erika Vucko, Melissa Lah, Amarilis Sanchez‐Valle, Brittany M. Murray, Amy Kritzer, Stephanie Sacharow   +7 more
wiley   +1 more source

Adult-Onset Still's Disease: A Diagnostic Odyssey and Therapeutic Triumph. [PDF]

Cureus
Ottu Para NK, Muhammed AH, Rab S.
europepmc   +1 more source

Dupilumab and Systemic Hematologic Malignancies: Case Series and Literature Review

JEADV Clinical Practice, Volume 5, Issue 1, Page 171-175, March 2026.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting 15%–20% of children and 3%–10% of adults. An increased risk of systemic lymphomas – but not leukemias – has been reported in patients with AD. Dupilumab, a monoclonal IgG4 antibody targeting IL‐4 and IL‐13 signaling, is approved for moderate‐to‐severe AD and is ...
Nello Tommasino, Cataldo Patruno, Francesca di Vico, Maddalena Napolitano   +3 more
wiley   +1 more source

Pro-Inflammatory Cytokines as Early Predictors of Chronic Rheumatologic Disease Following Chikungunya Virus Infection. [PDF]

J Clin Med
Conforti A, Lavalle G, Varini F, Lucchetti L, Cataldi G, Faticoni A, Ruggiero M, Gentile M, Gimignani G, Bassetti M.   +9 more
europepmc   +1 more source

Weekly Subcutaneous VK2735, a GIP/GLP‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study

Obesity, Volume 34, Issue 3, Page 537-549, March 2026.
Four doses of VK2735 and a placebo group were included in the VENTURE study. Adults who were overweight or had obesity had significant weight loss when taking any dose of VK2735 for 13 weeks. More people lost at least 10% of their body weight as the dose increased.
Harold E. Bays, Phillip Toth, Naim Alkhouri, John Pullman, Bradley Freilich, Joel Neutel, Summer Ji, Scott Stubbe, Parke Hedges, Brian Lian   +9 more
wiley   +1 more source